HK1143086A1 - The use of monomycolyl glycerol (mmg) as an adjuvant - Google Patents

The use of monomycolyl glycerol (mmg) as an adjuvant

Info

Publication number
HK1143086A1
HK1143086A1 HK10109721.5A HK10109721A HK1143086A1 HK 1143086 A1 HK1143086 A1 HK 1143086A1 HK 10109721 A HK10109721 A HK 10109721A HK 1143086 A1 HK1143086 A1 HK 1143086A1
Authority
HK
Hong Kong
Prior art keywords
mmg
adjuvant
monomycolyl glycerol
monomycolyl
glycerol
Prior art date
Application number
HK10109721.5A
Other languages
English (en)
Inventor
Else Marie Agger
Claire Andersen
Peter Andersen
Gurdyal Bersra
David Minikin
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of HK1143086A1 publication Critical patent/HK1143086A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK10109721.5A 2007-06-29 2010-10-14 The use of monomycolyl glycerol (mmg) as an adjuvant HK1143086A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700965 2007-06-29
PCT/DK2008/000239 WO2009003474A1 (en) 2007-06-29 2008-06-26 The use of monomycolyl glycerol (mmg) as an adjuvant

Publications (1)

Publication Number Publication Date
HK1143086A1 true HK1143086A1 (en) 2010-12-24

Family

ID=39789976

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10109721.5A HK1143086A1 (en) 2007-06-29 2010-10-14 The use of monomycolyl glycerol (mmg) as an adjuvant

Country Status (18)

Country Link
US (1) US8563009B2 (ja)
EP (1) EP2167124B1 (ja)
JP (1) JP5689314B2 (ja)
KR (1) KR101520512B1 (ja)
CN (1) CN101790384B (ja)
AU (1) AU2008271756B2 (ja)
BR (1) BRPI0811796A2 (ja)
CA (1) CA2691840C (ja)
DK (1) DK2167124T3 (ja)
ES (1) ES2394729T3 (ja)
HK (1) HK1143086A1 (ja)
HR (1) HRP20120722T1 (ja)
IL (1) IL203016A (ja)
PL (1) PL2167124T3 (ja)
PT (1) PT2167124E (ja)
RU (1) RU2479317C2 (ja)
SI (1) SI2167124T1 (ja)
WO (1) WO2009003474A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2047860A1 (en) * 2007-10-12 2009-04-15 Centre National De La Recherche Scientifique (Cnrs) Phamaceutical compositons comprosing actinomycete glycerol acyl derivatives antigens, their process of extractin, and their use against tuberculosis.
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2013004234A2 (en) * 2011-07-04 2013-01-10 Statens Serum Institut Methods for producing liposomes
RU2497541C1 (ru) * 2012-07-20 2013-11-10 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическая композиция на основе лигандов паттерн-распознающих рецепторов, способ ее использования в качестве иммуностимулятора для лечения инфекций, вызванных бактериальными и вирусными патогенами, способ ее использования в качестве адъюванта в составе вакцин
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
RU2615440C2 (ru) * 2015-05-25 2017-04-04 Илья Владимирович Духовлинов Гибридный белок, ДНК, генетическая конструкция, рекомбинантная клетка, вакцина на основе гибридного белка для профилактики и лечения туберкулеза (варианты)
SG10202104058XA (en) 2015-10-14 2021-05-28 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
EP3774829A2 (en) 2018-04-13 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunigenic alpha-branched trehalose-diesters
TW202019468A (zh) * 2018-08-03 2020-06-01 國立大學法人東京大學 誘導細胞性免疫之經鼻疫苗
KR20230002680A (ko) * 2020-04-15 2023-01-05 스태튼스 세룸 인스티튜트 병원성 감염의 예방 또는 조기 치료 용도의 리포솜 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243663A (en) 1976-06-25 1981-01-06 Ichiro Azuma Glycolipid compositions for transplanted tumor immunotherapy
DE2965017D1 (en) 1978-12-22 1983-04-14 Anvar New compounds associating peptidyl or aminoacyl residues to lipophilic groups and pharmaceutical compositions containing said new compounds
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
DK79793D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
WO2001048154A1 (fr) * 1999-12-28 2001-07-05 Toyoshima, Kumao Agent de maturation pour cellules dendritiques immatures
WO2002102407A1 (en) 2001-06-15 2002-12-27 Nordic Vaccine Technology A/S Therapeutical vaccination
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US7997037B2 (en) * 2003-06-23 2011-08-16 Ppg Industries Ohio, Inc. Integrated window sash with groove for desiccant material
KR100992646B1 (ko) * 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
JP4951338B2 (ja) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉ｒｎａ
US20050025710A1 (en) 2003-07-29 2005-02-03 Michel Schneider Reconstitutable formulation and aqueous suspension of gas-filled microvesicles for diagnostic imaging
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
ATE406874T1 (de) 2004-07-07 2008-09-15 Statens Seruminstitut Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden
US7820939B2 (en) * 2004-07-27 2010-10-26 The Regents Of The University Of Michigan Zero-gap laser welding
EP1910409A2 (en) 2005-06-23 2008-04-16 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP2402024A1 (en) 2006-06-28 2012-01-04 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4

Also Published As

Publication number Publication date
ES2394729T3 (es) 2013-02-05
HRP20120722T1 (hr) 2012-10-31
CN101790384B (zh) 2013-12-11
WO2009003474A1 (en) 2009-01-08
PL2167124T3 (pl) 2012-12-31
CA2691840C (en) 2016-08-09
US8563009B2 (en) 2013-10-22
US20100310585A1 (en) 2010-12-09
CN101790384A (zh) 2010-07-28
JP2010531820A (ja) 2010-09-30
KR20100045449A (ko) 2010-05-03
AU2008271756A1 (en) 2009-01-08
KR101520512B1 (ko) 2015-05-14
BRPI0811796A2 (pt) 2020-04-28
AU2008271756B2 (en) 2012-10-04
CA2691840A1 (en) 2009-01-08
SI2167124T1 (sl) 2012-12-31
RU2479317C2 (ru) 2013-04-20
EP2167124A1 (en) 2010-03-31
IL203016A (en) 2013-06-27
JP5689314B2 (ja) 2015-03-25
RU2010101274A (ru) 2011-08-10
PT2167124E (pt) 2012-11-12
DK2167124T3 (da) 2012-10-29
EP2167124B1 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
HK1143086A1 (en) The use of monomycolyl glycerol (mmg) as an adjuvant
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
EP2344522A4 (en) COMBINATION ADJUVANT FORMULATION
SI2310046T1 (sl) Novi adjuvansni sestavki
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
EP2249839A4 (en) FULVESTRANTFORMULIERUNGEN
GB0815435D0 (en) Formulations
GB0720716D0 (en) Novel formulation
IL206467A0 (en) Formulation
EP2435446B8 (en) Fluorinated silylethynyl pentacene compounds and compositions and methods of making and using the same
IL213475A0 (en) Assembly for the use of alternative energy
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS
GB0805356D0 (en) Vaccine adjuvant composition
PL1990355T3 (pl) Zastosowanie adduktów tlenku propylenu
ITMI20071261A1 (it) Procedimento per la preparazione di cinacalcet
PL2171061T3 (pl) Preparat esterazy
EP2221062A4 (en) NEW ADJUVANT
GB0712972D0 (en) Formulation
IT1391776B1 (it) Procedimento per la preparazione di dexlansoprazolo
ITMI20080888A1 (it) Procedimento per la preparazione di zileuton
PL381556A1 (pl) Sposób otrzymywania modyfikowanych (poli)siloksanów
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
PL381142A1 (pl) Sposób otrzymywania glicydolu
IT1398273B1 (it) Procedimento per la preparazione di 14-bromo daunomicina
GB0822394D0 (en) Formulations